» Articles » PMID: 26861926

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2016 Feb 11
PMID 26861926
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Nonalcoholic steatohepatitis (NASH) is increasingly common in obese patients. However, its metabolic consequences in patients with type 2 diabetes mellitus (T2DM) are unknown.

Research Design And Methods: We studied 154 obese patients divided in four groups: 1) control (no T2DM or NAFLD), 2) T2DM without NAFLD, 3) T2DM with isolated steatosis, and 4) T2DM with NASH. We evaluated intrahepatic triglycerides by proton MRS ((1)H-MRS) and assessed insulin secretion/resistance during an oral glucose tolerance test and a euglycemic-hyperinsulinemic clamp with glucose turnover measurements.

Results: No significant differences among groups were observed in sex, BMI, or total body fat. Metabolic parameters worsened progressively with the presence of T2DM and the development of hepatic steatosis, with worse hyperinsulinemia, insulin resistance, and dyslipidemia (hypertriglyceridemia and low HDL cholesterol) in those with NASH (P < 0.001). Compared with isolated steatosis, NASH was associated with more dysfunctional and insulin-resistant adipose tissue (either as insulin suppression of plasma FFA [33 ± 3 vs. 48 ± 6%] or adipose tissue insulin resistance index [9.8 ± 1.0 vs. 5.9 ± 0.8 mmol/L ⋅ µIU/mL]; both P < 0.03). Furthermore, insulin suppression of plasma FFA correlated well with hepatic steatosis (r = -0.62; P < 0.001) and severity of steatohepatitis (rs = -0.52; P < 0.001). Hepatic insulin sensitivity was also more significantly impaired among patients with T2DM and NASH, both fasting and with increasing insulin levels within the physiological range (10 to 140 µIU/mL), compared with other groups.

Conclusions: In obese patients with T2DM, the presence of NAFLD is associated with more severe hyperinsulinemia, dyslipidemia, and adipose tissue/hepatic insulin resistance compared with patients without NAFLD. The unfavorable metabolic profile linked to NAFLD should prompt strategies to identify and treat this population early on.

Citing Articles

Metabolic Dysfunction-associated Steatotic Liver Disease and Type 2 Diabetes: A Deadly Synergy.

Leith D, Lin Y, Brennan P touchREV Endocrinol. 2024; 20(2):5-9.

PMID: 39526052 PMC: 11548366. DOI: 10.17925/EE.2024.20.2.2.


Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants.

Bril F, Kalavalapalli S, Lomonaco R, Frye R, Godinez Leiva E, Cusi K JHEP Rep. 2024; 6(7):101092.

PMID: 39022386 PMC: 11252529. DOI: 10.1016/j.jhepr.2024.101092.


Effects of Leaf Extract on Liver Histopathology: A Systematic Review.

Nurhayati T, Ridho M, Santoso P, Setiawan S, Goenawan H, Tarawan V J Nutr Metab. 2024; 2024:6815993.

PMID: 38993633 PMC: 11239234. DOI: 10.1155/2024/6815993.


Glucagon-like Peptide-1 Receptor Agonists-A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD).

Choi E, Ramirez Tovar A, He Z, Soler Rodriguez D, Vos M, Arora S Children (Basel). 2024; 11(3).

PMID: 38539310 PMC: 10969291. DOI: 10.3390/children11030275.


Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care.

Nogueira J, Cusi K Diabetes Spectr. 2024; 37(1):20-28.

PMID: 38385099 PMC: 10877218. DOI: 10.2337/dsi23-0013.


References
1.
Perman W, Balci N, Akduman I . Review of magnetic resonance spectroscopy in the liver and the pancreas. Top Magn Reson Imaging. 2009; 20(2):89-97. DOI: 10.1097/RMR.0b013e3181c422f1. View

2.
Bril F, Lomonaco R, Orsak B, Ortiz-Lopez C, Webb A, Tio F . Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology. 2014; 59(6):2178-87. DOI: 10.1002/hep.26988. View

3.
Fabbrini E, Sullivan S, Klein S . Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2009; 51(2):679-89. PMC: 3575093. DOI: 10.1002/hep.23280. View

4.
Adams L, Harmsen S, St Sauver J, Charatcharoenwitthaya P, Enders F, Therneau T . Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol. 2010; 105(7):1567-73. PMC: 2898908. DOI: 10.1038/ajg.2010.18. View

5.
Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D . The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology. 2014; 61(1):153-60. DOI: 10.1002/hep.27395. View